Proteasome regulators in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pancreatic adenocarcinoma is a highly lethal cancer with increasing incidence and poor prognosis, especially in metastatic stages.
• Despite advances in chemotherapy, long-term survival remains rare.
• Molecular insights reveal common genetic lesions driving pancreatic carcinogenesis.

Purpose of the Study:

• To review the role of the proteasome and its regulating transcription factors in pancreatic cancer.
• To explore the interplay between proteasome networks and dysregulated signaling pathways (e.g., KRAS/BRAF/MAPK, TGF-β/SMAD).
• To discuss the implications of stemness and the therapeutic potential of proteasome inhibitors.

Main Methods:

• Literature review focusing on proteostasis, transcription factors, and signaling pathways in pancreatic cancer.
• Analysis of molecular characterization data and therapeutic strategies.
• Discussion of the cellular micro-environment and stemness in pancreatic carcinogenesis.

Main Results:

• Proteostasis regulation via the proteasome is critical for cancer cell metabolism.
• Key transcription factors (FOXO, NFE2L2, hHSF1/2, NF-Y) regulate proteasome units.
• Dysregulated pathways and proteasome regulators contribute to pancreatic cancer progression.

Conclusions:

• The proteasome and its regulatory networks are central to pancreatic cancer biology.
• Understanding these mechanisms is crucial for developing effective therapies.
• Proteasome inhibitors represent a promising therapeutic avenue for pancreatic cancer treatment.